Substituted diazaspiroalkanes as androgen receptor modulators

1. A method for treating a patient with a hyperproliferative disorder, comprising administering to a patient in need thereof a pharmaceutical composition comprising a pharmaceutically acceptable carrier, diluent, or adjuvant and a compound of Formula II:

or a pharmaceutically acceptable salt thereof,

wherein:

A is S;

B is O;

Het is pyridyl, optionally substituted with 1, 2, 3, or 4 substituents independently selected from the group consisting of halogen, cyano, nitro, alkyl, alkenyl, alkynyl, NR 11 R 12 , NR 12 C(O)R 11 , NHC(O)NR 11 R 12 , NHC(O)OR 11 , NR 12 C(S)R 11 , NHC(S)NR 11 R 12 , NR 12 C(S)OR 11 , OR 11 , OC(O)R 11 , OC(O)OR 11 , OC(S)R 11 , SR 11 , and aryl;

R 1 is aryl;

R 2 and R 3 , together with the carbon atom to which they are linked, form a C 3-10 cycloalkyl;

R 11 is hydrogen, alkyl, alkenyl, alkynyl, heterocyclic non-aromatic, aryl, or heterocyclic aromatic; and

R 12 is hydrogen, alkyl, alkenyl, alkynyl, heterocyclic non-aromatic, aryl, or heterocyclic aromatic;

wherein each alkyl is optionally substituted with 1 or more substituents independently selected from the group consisting of fluoro, chloro, bromo, iodo, cyano, nitro, alkyl, carbalkoyl, alkenyl, amido, carboxy, amino, hydroxy, alkoxy, thiol, alkylthio, heterocyclyl, aryl, and heteroaryl;

wherein each alkenyl, alkynyl, or substituted heterocyclic non-aromatic is optionally substituted with 1 or more substituents independently selected from the group consisting of halogen, cyano, nitro, oxo, alkyl, carbalkoyl, arylalkyl, alkenyl, acyl, amido, alkylamido, carboxy, amino, alkanoylamino, arylcarbonylamino, hydroxy, alkoxy, aryloxy, thiol, alkylthio, cycloalkyl, heterocyclyl, aryl, and heteroaryl;

wherein each aryl is optionally substituted with 1 or more substituents independently selected from the group consisting of halogen, cyano, nitro, alkyl, haloalkyl, carbalkoyl, amidified carboxyalkyl, alkyl amidified carboxyalkyl, aryloxyalkyl, arylthioalkyl, arylsulfinylalkyl, cycloalkylalkyl, cycloheteroalkylalkyl, arylalkyl, heteroarylalkyl, alkenyl, arylalkenyl, heteroarylalkenyl, alkynyl, alkylcarbonyl, amido, alkylaminocarbonyl, arylaminocarbonyl, arylsulfonaminocarbonyl, carboxy, alkoxycarbonyl, arylcarbonyl, amino, alkylcarbonylamino, carbamoyl, alkylcarbamoyl, arylsulfonylamino, arylazo, hydroxy, alkoxy, haloalkoxy, arylalkoxy, alkylcarbonyloxy, arylcarbonyloxy, aryloxy, heteroaryloxy, thiol, alkylthio, arylthio, alkoxyarylthio, heteroarylthio, arylsulfinyl, cycloalkyl, heterocyclyl, aryl, aminocarbonylaryl, heteroaryl, and heteroarylheteroaryl;

wherein each amino substituent of each aryl is optionally substituted with 1 or 2 substituents independently selected from the group consisting of alkyl, aryloxyalkyl, arylthioalkyl, arylsulfinylalkyl, arylalkyl, heteroarylalkyl, arylalkenyl, heteroarylalkenyl, arylalkynyl, arylaminocarbonyl, arylsulfonaminocarbonyl, arylcarbonyl, arylazo, arylcarbonylamino, arylalkoxy, arylcarbonyloxy, aryloxy, heteroaryloxy, arylthio, alkoxyarylthio, heteroarylthio, arylsulfinyl, aryl, aminocarbonylaryl, heteroaryl, and heteroarylheteroaryl; and

wherein each heteroaryl or heterocyclic aromatic is optionally substituted with 1, 2, 3, or 4 substituents independently selected from the group consisting of halogen, cyano, nitro, oxo, alkyl, carbalkoyl, arylalkyl, alkenyl, acyl, amido, alkylamido, carboxy, amino, alkanoylamino, arylcarbonylamino, hydroxy, alkoxy, aryloxy, thiol, alkylthio, cycloalkyl, aryl, heterocyclyl, and heteroaryl;

provided that the compound is not:

2. The method of claim 1 , wherein:

Het is:

wherein:

R 4 is hydrogen, halogen, cyano, nitro, C 1-8 alkyl, or OR 11 , wherein the C 1-8 alkyl is optionally substituted with 1 or more substituents independently selected from the group consisting of fluoro, chloro, bromo, and iodo;

R 5 is hydrogen, halogen, cyano, nitro, C 1-8 alkyl, or OR 11 , wherein the C 1-8 alkyl is optionally substituted with 1 or more substituents independently selected from the group consisting of fluoro, chloro, bromo, and iodo;

R 6 is hydrogen, halogen, cyano, nitro, C 1-8 alkyl, or OR 11 , wherein the C 1-8 alkyl is optionally substituted with 1 or more substituents independently selected from the group consisting of fluoro, chloro, bromo, and iodo; and

R 7 is hydrogen, halogen, cyano, nitro, C 1-8 alkyl, or OR 11 , wherein the C 1-8 alkyl is optionally substituted with 1 or more substituents independently selected from the group consisting of fluoro, chloro, bromo, and iodo;

provided that R 4 , R 5 , R 6 , and R 7 are not all hydrogen.

3. The method of claim 2 , wherein Het is:

4. The method of claim 2 , wherein:

(i) R 4 is cyano or nitro;

R 5 is hydrogen, halogen, C 1-8 alkyl, or OC 1-8 alkyl, wherein the C 1-8 alkyl and OC 1-8 alkyl are optionally substituted with 1 or more fluoro substituents;

R 6 is hydrogen; and

R 7 is hydrogen; or

(ii) R 4 is hydrogen, halogen, C 1-8 alkyl, or OC 1-8 alkyl, wherein the C 1-8 alkyl and OC 1-8 alkyl are optionally substituted with 1 or more fluoro substituents;

R 5 is cyano or nitro;

R 6 is hydrogen; and

R 7 is hydrogen.

5. The method of claim 2 , wherein:

R 4 is cyano or nitro;

R 5 is hydrogen, halogen, C 1-8 alkyl, or OC 1-8 alkyl, wherein the C 1-8 alkyl and OC 1-8 alkyl are optionally substituted with 1 or more fluoro substituents;

R 6 is hydrogen; and

R 7 is hydrogen.

6. The method of claim 1 , wherein R 1 is substituted phenyl.

7. The method of claim 1 , wherein:

(i) R 1 is phenyl, substituted with 1 or more fluoro; or

(ii) R 1 is phenyl, substituted with 1 or more C 1-6 alkyl; or

(iii) R 1 is phenyl, substituted with 1 carbamoyl; or

(iv) R 1 is phenyl, substituted with 1 or more C 1-8 aklaminocarbonyl.

8. The method of claim 1 , wherein R 2 and R 3 , together with the carbon atom to which they are linked, form a C 3-6 cycloalkyl.

9. The method of claim 1 , wherein R 2 and R 3 , together with the carbon atom to which they are linked, form a cyclobutyl.

10. The method of claim 1 , wherein the hyperproliferative disorder is prostate cancer.

11. The method of claim 1 , wherein the hyperproliferative disorder is hormone refractory prostate cancer.

12. The method of claim 1 , wherein the hyperproliferative disorder is hormone sensitive prostate cancer.

13. The method of claim 1 , wherein the pharmaceutical composition is administered orally.

14. The method of claim 1 , wherein the pharmaceutical composition is a unit dosage form comprising from 0.0005 mg to 500 mg of the compound of Formula II, or a pharmaceutically acceptable salt thereof, per unit dosage form.

15. The method of claim 1 , wherein the pharmaceutical composition is administered daily to the patient in an amount to provide the patient with a dosage of the compound of Formula II, or a pharmaceutically acceptable salt thereof, in the range of from 0.01 mg per kg of body weight to 500 mg per kg of body weight.